Miquel Quesada

Miquel Quesada

Auto-generated profile, based on publicly available information

Miquel Quesada

Family Medicine Research Unit and Primary Health Care Research Unit Institute Jordi Gol, Catalan Institute of Health, Girona, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2016 in Diabetes Care
Verified
Journal Article
Open access
PDF file
JBJose Miguel Baena-Díez
Jose Miguel Baena-Díez
JPJudit Peñafiel
Judit Peñafiel
ISIsaac Subirana
Isaac Subirana
RRRafel Ramos
Rafel Ramos
RERoberto Elosua
Roberto Elosua
OIon behalf of the FRESCO Investigators
on behalf of the FRESCO Investigators
OBJECTIVE: Diabetes is a common cause of shortened life expectancy. We aimed to assess the association between diabetes and cause-specific death. RESEARCH DESIGN AND METHODS: We used the pooled analysis of individual data from 12 Spanish population cohorts with 10-year follow-up. Participants had no previous history of cardiovascular diseases and were 35–79 years old. Diabetes status was self-reported or defined as glycemia >125 mg/dL at baseline. Vital status and causes of death were ascertained by medical records review and linkage with the official death registry. The hazard ratios and cumulative mortality function were assessed with two approaches, with and without competing risks: proportional subdistribution hazard (PSH) and cause-specific hazard (CSH), respectively. Multivariate analyses were fitted for cardiovascular, cancer, and noncardiovascular noncancer deaths. RESULTS: We included 55,292 individuals (15.6% with diabetes and overall mortality of 9.1%). The adjusted hazard ratios showed that diabetes increased mortality risk: 1) cardiovascular death, CSH = 2.03 (95% CI 1.63–2.52) and PSH = 1.99 (1.60–2.49) in men; and CSH = 2.28 (1.75–2.97) and PSH = 2.23 (1.70–2.91) in women; 2) cancer death, CSH = 1.37 (1.13–1.67) and PSH = 1.35 (1.10–1.65) in men; and CSH = 1.68 (1.29–2.20) and PSH = 1.66 (1.25–2.19) in women; and 3) noncardiovascular noncancer death, CSH = 1.53 (1.23–1.91) and PSH = 1.50 (1.20–1.89) in men; and CSH = 1.89 (1.43–2.48) and PSH = 1.84 (1.39–2.45) in women. In all instances, the cumulative mortality function was significantly higher in individuals with diabetes. CONCLUSIONS: Diabetes is associated with premature death from cardiovascular disease, cancer, and noncardiovascular noncancer causes. The use of CSH and PSH provides a comprehensive view of mortality dynamics in a population with diabetes.

1 September 2009 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
RRRafel Ramos
Rafel Ramos
MQM. Quesada
M. Quesada
PSP. Solanas
P. Solanas
ISI. Subirana
I. Subirana
JSJ. Sala
J. Sala
JMJaume Marrugat
Jaume Marrugat

1 February 2016 in JACC
Verified
Journal Article
Open access
RRRafel Ramos
Rafel Ramos
MGMaria García-Gil
Maria García-Gil
MCMarc Comas-Cufí
Marc Comas-Cufí
MQMiquel Quesada
Miquel Quesada
JMJaume Marrugat
Jaume Marrugat
BBBonaventura Bolíbar
Bonaventura Bolíbar
Evidence is lacking about the effectiveness of risk reduction interventions in patients with asymptomatic peripheral arterial disease. This study aimed to assess whether statin therapy was associated with a reduction in major adverse cardiovascular events (MACE) and mortality in this population. Data were obtained from 2006 through 2013 from the Catalan primary care system's clinical records database (SIDIAP). Patients age 35 to 85 years with an ankle-brachial index ≤0.95 and without clinically recognized cardiovascular disease (CVD) were included. Participants were categorized as statins nonusers or new-users (first prescription or represcribed after at least 6 months) and matched 1:1 by inclusion date and propensity score for statin treatment. Conditional Cox proportional hazards modeling was used to compare the groups for the incidence of MACE (myocardial infarction, cardiac revascularization, and ischemic stroke) and all-cause mortality. The matched-pair cohort included 5,480 patients (mean age 67 years; 44% women) treated/nontreated with statins. The 10-year coronary heart disease risk was low (median: 6.9%). Median follow-up was 3.6 years. Incidence of MACE was 19.7 and 24.7 events per 1,000 person-years in statin new-users and nonusers, respectively. Total mortality rates also differed: 24.8 versus 30.3 per 1,000 person-years, respectively. Hazards ratios were 0.80 for MACE and 0.81 for overall mortality. The 1-year number needed to treat was 200 for MACE and 239 for all-cause mortality. Statin therapy was associated with a reduction in MACE and all-cause mortality among participants without clinical CVD but with asymptomatic peripheral arterial disease, regardless of its low CVD risk. The absolute reduction was comparable to that achieved in secondary prevention.

1 April 2014 in Preventive Medicine
Verified
Journal Article
Closed access
JMJaume Marrugat
Jaume Marrugat
ISIsaac Subirana
Isaac Subirana
RRRafel Ramos
Rafel Ramos
JVJoan Vila
Joan Vila
AMAlejandro Marín-Ibañez
Alejandro Marín-Ibañez
RERoberto Elosua
Roberto Elosua

1 January 2012 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
RRRafel Ramos
Rafel Ramos
EBElisabet Balló
Elisabet Balló
JMJaume Marrugat
Jaume Marrugat
RERoberto Elosua
Roberto Elosua
JSJoan Sala
Joan Sala
MQMiquel Quesada
Miquel Quesada

13 October 2011 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
RLRuth Martí Lluch
Ruth Martí Lluch
DPDídac Parramon
Dídac Parramon
LOLUIS Garcia Ortiz
LUIS Garcia Ortiz
FRFernando Rigo
Fernando Rigo
MGManuel Angel Gómez Gómez-Marcos
Manuel Angel Gómez Gómez-Marcos
RRRafel Ramos
Rafel Ramos
Background: Cardiovascular risk functions fail to identify more than 50% of patients who develop cardiovascular disease. This is especially evident in the intermediate-risk patients in which clinical management becomes difficult. Our purpose is to analyze if ankle-brachial index (ABI), measures of arterial stiffness, postprandial glucose, glycosylated hemoglobin, self-measured blood pressure and presence of comorbidity are independently associated to incidence of vascular events and whether they can improve the predictive capacity of current risk equations in the intermediate-risk population. Methods/Design: This project involves 3 groups belonging to REDIAPP (RETICS RD06/0018) from 3 Spanish regions. We will recruit a multicenter cohort of 2688 patients at intermediate risk (coronary risk between 5 and 15% or vascular death risk between 3-5% over 10 years) and no history of atherosclerotic disease, selected at random. We will record socio-demographic data, information on diet, physical activity, comorbidity and intermittent claudication. We will measure ABI, pulse wave velocity and cardio ankle vascular index at rest and after a light intensity exercise. Blood pressure and anthropometric data will be also recorded. We will also quantify lipids, glucose and glycosylated hemoglobin in a fasting blood sample and postprandial capillary glucose. Eighteen months after the recruitment, patients will be followed up to determine the incidence of vascular events (later follow-ups are planned at 5 and 10 years). We will analyze whether the new proposed risk factors contribute to improve the risk functions based on classic risk factors. Discussion: Primary prevention of cardiovascular diseases is a priority in public health policy of developed and developing countries. The fundamental strategy consists in identifying people in a high risk situation in which preventive measures are effective and efficient. Improvement of these predictions in our country will have an immediate, clinical and welfare impact and a short term public health effect. Trial Registration: Clinical Trials.gov Identifier: NCT01428934